Antiepileptic drug development for "therapeutic orphans"

Related Experiment Video

Updated: Sep 20, 2026

Electrophoretic Delivery of γ-aminobutyric Acid (GABA) into Epileptic Focus Prevents Seizures in Mice
07:01

Electrophoretic Delivery of γ-aminobutyric Acid (GABA) into Epileptic Focus Prevents Seizures in Mice

Published on: May 16, 2019

Edwin Trevathan1

  • 1Pediatric Epilepsy Center, Department of Neurology, Washington University School of Medicine, St. Louis Children's Hospital, St. Louis, Missouri 63110-1093, USA.

Epilepsia
|August 16, 2003
PubMed

Insights

Children with epilepsy are "therapeutic orphans" due to a lack of specific drug development. New government-funded initiatives and industry incentives are needed for pediatric antiepileptic drug (AED) research.

Area of Science:

  • Pediatric Neurology
  • Clinical Pharmacology
  • Drug Development

Background:

  • Epilepsy is the most common serious pediatric neurological disorder, with many unique childhood-onset syndromes.
  • Current antiepileptic drug (AED) trials primarily use adult-tested medications, leaving children underserved.
  • Children with epilepsy are considered "therapeutic orphans" due to limited drug development tailored to their needs.

Purpose of the Study:

  • To highlight the challenges and barriers in developing AEDs specifically for children.
  • To advocate for systemic changes to improve pediatric epilepsy treatment.

Main Methods:

  • Review of current AED drug development practices for pediatric populations.
  • Analysis of ethical, practical, financial, and regulatory hurdles.
  • Comparison with successful pediatric research models like the Children's Oncology Group (COG).

Main Results:

  • Pediatric epilepsy drug development faces significant challenges, including the rapid evolution of syndromes and difficulty distinguishing drug effects from natural disease progression.
  • Ethical considerations, logistical issues (e.g., monitoring), and financial/regulatory disincentives hinder industry investment.
  • The current system prioritizes adult epilepsy drugs, often failing to meet the specific needs of pediatric epilepsy syndromes.

Conclusions:

  • Urgent need for a dedicated, government-funded pediatric epilepsy research consortium.
  • Recommendations include regulatory adjustments and financial incentives to encourage pharmaceutical industry investment in pediatric AEDs.
  • Developing novel AEDs specifically for children is crucial to address the unmet needs of this vulnerable population.

More Related Videos

Pentylenetetrazole-Induced Kindling Mouse Model07:06

Pentylenetetrazole-Induced Kindling Mouse Model

Published on: June 12, 2018

Preparation and Implantation of Electrodes for Electrically Kindling VGAT-Cre Mice to Generate a Model for Temporal Lobe Epilepsy09:29

Preparation and Implantation of Electrodes for Electrically Kindling VGAT-Cre Mice to Generate a Model for Temporal Lobe Epilepsy

Published on: August 17, 2021

Related Concept Videos

Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
Antiepileptic Drugs: Sodium Channel Blockers01:08

Antiepileptic Drugs: Sodium Channel Blockers

Antiepileptic drugs are specialized medications that prevent seizures in individuals diagnosed with epilepsy. These drugs primarily function by blocking the movement of sodium ions through channels in the neuronal membrane, inhibiting the repetitive firing of action potentials often associated with seizures.
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...